Kedrion Biopharma
Simon Weatherley is an experienced regulatory affairs professional with a strong background in regulatory operations and submission management. Currently serving as a Senior Specialist in RA Systems & Publishing at Kedrion Biopharma since April 2024, Simon is responsible for the planning and creation of eCTD dossiers, as well as managing regulatory affairs archiving and databases. Previous roles include Manager of Regulatory Operations and Systems at Orchard Therapeutics, where Simon managed submission packages, and Regulatory Affairs Manager at Teva Pharmaceuticals, overseeing a team responsible for regulatory submissions. With foundational experience in publishing regulatory submissions for vaccines at GSK and Novartis, alongside earlier roles focused on electronic regulatory publishing and informatics, Simon brings a comprehensive skill set to the field. Simon holds a BSc (Hons) in Earth Studies from Aberystwyth University.
This person is not in any teams
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.